Eli Lilly launches cancer drug Tanstrive in India, priced at INR 215,000/box
This story was originally published at 19:30 IST on 25 June 2026
Register to read our real-time news.Informist, Thursday, Jun. 25, 2026
NEW DELHI – Eli Lilly and Co. India Pvt. Ltd. has launched a cancer drug Tanstrive after receiving marketing authorisation from the Central Drugs Standard Control Organisation. The company has priced the drug at INR 215,000 per box, which will contain tablets for a 14-day treatment to be taken twice daily. It is available in 40 milligrams, 80 mg, 120 mg, and 160 mg strengths.
The drug is used for patients with advanced or metastatic cancer. Tanstrive is the first selective rearranged during transfection inhibitor approved in India for treating rearranged during transfection-altered solid tumours, irrespective of tumour type, the company said. End
Reported by Gunjan Rajput
Edited by Saji George Titus
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
